Cargando…

Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review

INTRODUCTION: Primary hyperparathyroidism is increasingly an asymptomatic disease at diagnosis, but the recognized guidelines for management are based on evidence obtained from studies on patients with symptomatic disease, and surgery is not always indicated. Other patients are unable to undergo sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Leere, Julius Simoni, Karmisholt, Jesper, Robaczyk, Maciej, Vestergaard, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397399/
https://www.ncbi.nlm.nih.gov/pubmed/28473803
http://dx.doi.org/10.3389/fendo.2017.00079
_version_ 1783230238008803328
author Leere, Julius Simoni
Karmisholt, Jesper
Robaczyk, Maciej
Vestergaard, Peter
author_facet Leere, Julius Simoni
Karmisholt, Jesper
Robaczyk, Maciej
Vestergaard, Peter
author_sort Leere, Julius Simoni
collection PubMed
description INTRODUCTION: Primary hyperparathyroidism is increasingly an asymptomatic disease at diagnosis, but the recognized guidelines for management are based on evidence obtained from studies on patients with symptomatic disease, and surgery is not always indicated. Other patients are unable to undergo surgery, and thus a medical treatment is warranted. This systematic review provides an overview of the existing literature on contemporary pharmaceutical options available for the medical management of primary hyperparathyroidism. METHODS: Databases of medical literature were searched for articles including terms for primary hyperparathyroidism and each of the included drugs. Data on s-calcium, s-parathyroid hormone, bone turnover markers, bone mineral density (BMD) and hard endpoints were extracted and tabulated, and level of evidence was determined. Changes in s-calcium were estimated and a meta-regression analysis was performed. RESULTS: The 1,999 articles were screened for eligibility and 54 were included in the review. Weighted mean changes calculated for each drug in s-total calcium (mean change from baseline ± SEM) were pamidronate (0.31 ± 0.034 mmol/l); alendronate (0.07 ± 0.05 mmol/l); clodronate (0.20 ± 0.040 mmol/l); mixed bisphosphonates (0.16 ± 0.049 mmol/l); and cinacalcet (0.37 ± 0.013 mmol/l). The meta-analysis revealed a significant decrease of effect on s-calcium with time for the bisphosphonates (Coef. −0.049 ± 0.023, p = 0.035), while cinacalcet proved to maintain its effect on s-calcium over time. Bisphosphonates improved BMD while cinacalcet had no effect. DISCUSSION: The included studies demonstrate advantages and drawbacks of the available pharmaceutical options that can prove helpful in the clinical setting. The great variation in how primary hyperparathyroidism is manifested requires that management should rely on an individual evaluation when counseling patients. Combining resorptive agents with calcimimetics could prove rewarding, but more studies are warranted.
format Online
Article
Text
id pubmed-5397399
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-53973992017-05-04 Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review Leere, Julius Simoni Karmisholt, Jesper Robaczyk, Maciej Vestergaard, Peter Front Endocrinol (Lausanne) Endocrinology INTRODUCTION: Primary hyperparathyroidism is increasingly an asymptomatic disease at diagnosis, but the recognized guidelines for management are based on evidence obtained from studies on patients with symptomatic disease, and surgery is not always indicated. Other patients are unable to undergo surgery, and thus a medical treatment is warranted. This systematic review provides an overview of the existing literature on contemporary pharmaceutical options available for the medical management of primary hyperparathyroidism. METHODS: Databases of medical literature were searched for articles including terms for primary hyperparathyroidism and each of the included drugs. Data on s-calcium, s-parathyroid hormone, bone turnover markers, bone mineral density (BMD) and hard endpoints were extracted and tabulated, and level of evidence was determined. Changes in s-calcium were estimated and a meta-regression analysis was performed. RESULTS: The 1,999 articles were screened for eligibility and 54 were included in the review. Weighted mean changes calculated for each drug in s-total calcium (mean change from baseline ± SEM) were pamidronate (0.31 ± 0.034 mmol/l); alendronate (0.07 ± 0.05 mmol/l); clodronate (0.20 ± 0.040 mmol/l); mixed bisphosphonates (0.16 ± 0.049 mmol/l); and cinacalcet (0.37 ± 0.013 mmol/l). The meta-analysis revealed a significant decrease of effect on s-calcium with time for the bisphosphonates (Coef. −0.049 ± 0.023, p = 0.035), while cinacalcet proved to maintain its effect on s-calcium over time. Bisphosphonates improved BMD while cinacalcet had no effect. DISCUSSION: The included studies demonstrate advantages and drawbacks of the available pharmaceutical options that can prove helpful in the clinical setting. The great variation in how primary hyperparathyroidism is manifested requires that management should rely on an individual evaluation when counseling patients. Combining resorptive agents with calcimimetics could prove rewarding, but more studies are warranted. Frontiers Media S.A. 2017-04-20 /pmc/articles/PMC5397399/ /pubmed/28473803 http://dx.doi.org/10.3389/fendo.2017.00079 Text en Copyright © 2017 Leere, Karmisholt, Robaczyk and Vestergaard. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Leere, Julius Simoni
Karmisholt, Jesper
Robaczyk, Maciej
Vestergaard, Peter
Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review
title Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review
title_full Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review
title_fullStr Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review
title_full_unstemmed Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review
title_short Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review
title_sort contemporary medical management of primary hyperparathyroidism: a systematic review
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5397399/
https://www.ncbi.nlm.nih.gov/pubmed/28473803
http://dx.doi.org/10.3389/fendo.2017.00079
work_keys_str_mv AT leerejuliussimoni contemporarymedicalmanagementofprimaryhyperparathyroidismasystematicreview
AT karmisholtjesper contemporarymedicalmanagementofprimaryhyperparathyroidismasystematicreview
AT robaczykmaciej contemporarymedicalmanagementofprimaryhyperparathyroidismasystematicreview
AT vestergaardpeter contemporarymedicalmanagementofprimaryhyperparathyroidismasystematicreview